CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Perception of prognosis, quality of life, and distress in patients receiving chimeric antigen receptor T-cell therapy.
Perception of prognosis, quality of life, and distress in patients receiving chimeric antigen receptor T-cell therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
接受 CAR-T 治疗的患者报告对其预后持过于乐观的认知,并且心理困扰发生率较高。对预后的情绪应对能力较强和适应性反应较好与更好的 QOL 和更少的心理困扰相关,凸显了开发干预措施以促进对该治疗应对的必要性。通俗语言总结:接受 CAR-T 细胞治疗的患者报告对其预后持过于乐观的认知,并且心理困扰发生率较高。值得注意的是,对预后的情绪应对能力较强和适应性反应较好与更好的生活质量和更少的心理困扰相关。
嵌合抗原受体(CAR)T细胞对血液系统恶性肿瘤患者可能具有治愈性,但可引起危及生命的毒性。关于预后认知和心理困扰的数据尚缺乏。
作者对接受CAR-T 的患者进行了一项横断面研究。在因CAR-T 住院前,患者完成了生活质量(QOL)评估(癌症治疗功能评估-通用版)、焦虑和抑郁症状评估(医院焦虑抑郁量表)以及创伤后应激障碍症状评估(创伤后应激检查表)。患者还完成了预后意识影响量表(PAIS),该量表测量三个领域:对预后的认知理解、对预后的情绪应对以及适应性反应。
共有71.8%(142例合格患者中的102例)的患者被纳入研究。共有34%的患者报告其肿瘤科医生表示他们的癌症可治愈,64%的患者报告治愈可能性>50%。总体而言,分别有26%、30%和21%的患者报告存在临床显著的抑郁、焦虑和创伤后应激障碍(PTSD)症状。我们发现患者对预后的认知理解与QOL或情绪之间没有关联。对预后的较高情绪应对与更好的QOL(= 0.72;SE = 0.10;p = <.001)以及较低的抑郁(= -0.17;SE = 0.02;p = <.001)、焦虑(= -0.21;SE = 0.02;p = <.001)和PTSD(= -0.43;SE = 0.06;p = <.001)症状相关。较高的适应性反应与更好的QOL(= 0.19;SE = 0.09;p = .028)以及较低的抑郁(= -0.05;SE = 0.02;p = .023)、焦虑(= -0.09;SE = 0.02;p = <.001)和PTSD(= -0.19;SE = 0.05;p = <.001)症状相关。
Chimeric antigen receptor (CAR) T-cell is potentially curative therapy for patients with hematologic malignancies but can cause life-threatening toxicities. Data on perceptions of prognosis and psychological distress are lacking.
The authors conducted a cross-sectional study of patients receiving CAR-T. Before hospitalization for CAR-T, patients completed assessments of quality of life (QOL) (Functional Assessment of Cancer Therapy-General), anxiety and depression symptoms (Hospital Anxiety and Depression Scale) and post-traumatic stress disorder symptoms (Post-Traumatic Stress Checklist). Patients also completed the Prognostic Awareness Impact Scale (PAIS), which measures three domains: cognitive understanding of prognosis, emotional coping with prognosis, and adaptive response.
A total of 71.8% (102 of 142) of eligible patients were enrolled. A total of 34% of patients reported that their oncologist said their cancer is curable and 64% reported there was >50% chance of cure. Overall, 26%, 30%, and 21% of patients reported clinically significant depression, anxiety, and posttraumatic stress disorder (PTSD) symptoms, respectively. We found no association between patients' cognitive understanding of prognosis and QOL or mood. Higher emotional coping with prognosis was associated with better QOL ( = 0.72; SE = 0.10; p = <.001) and lower depression ( = -0.17; SE = 0.02; p = <.001), anxiety ( = -0.21; SE = 0.02; p = <.001), and PTSD ( = -0.43; SE = 0.06; p = <.001) symptoms. Higher adaptive response was associated with better QOL ( = 0.19; SE = 0.09; p = .028) and lower depression ( = -0.05; SE = 0.02; p = .023), anxiety ( = -0.09; SE = 0.02; p = <.001), and PTSD ( = -0.19; SE = 0.05; p = <.001) symptoms.
Patients undergoing CAR-T report overly optimistic perception of their prognosis and have high rates of psychological distress. Higher emotional coping with prognosis and adaptive response were associated with better QOL and less psychological distress, underscoring the need to develop interventions to promote coping with this treatment. PLAIN LANGUAGE SUMMARY: Patients undergoing chimeric antigen receptor T-cell therapy experience report overly optimistic perceptions of their prognosis and have high rates of psychological distress. Notably, higher emotional coping with prognosis and adaptive response were associated with better quality of life and less psychological distress.
MEMBER ACCOUNT
登录成功会直接打开下一页。